• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期胆管癌患者静脉血栓栓塞的临床意义。

Clinical Significance of Venous Thromboembolism in Patients with Advanced Cholangiocarcinoma.

机构信息

Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.

Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea.

出版信息

Gut Liver. 2024 Jan 15;18(1):165-173. doi: 10.5009/gnl220477. Epub 2023 Apr 3.

DOI:10.5009/gnl220477
PMID:37009669
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10791496/
Abstract

BACKGROUND/AIMS: Patients with active cancer frequently develop venous thromboembolism (VTE). However, there is little data about VTE in patients with advanced cholangiocarcinoma (CCA). Therefore, we investigated the clinical significance of VTE in patients with advanced CCA.

METHODS

We analyzed the data of a total of 332 unresectable CCA patients diagnosed between 2010 and 2020 in this retrospective study. We investigated the incidence and risk factors for VTE, and its effect on survival in patients with advanced CCA.

RESULTS

During a median follow-up of 11.6 months, 118 patients (35.5%) developed VTE. The cumulative incidence of VTE was 22.4% (95% confidence interval [CI], 0.18 to 0.27) at 3 months and 32.8% (95% CI, 0.27 to 0.38) at 12 months. Major vessel invasion was an independent risk factor for VTE (hazard ratio, 2.88; 95% CI, 1.92 to 4.31; p<0.001). Patients who developed VTE during follow-up had shorter overall survival than patients who did not (11.50 months vs 15.83 months, p=0.005). In multivariable analysis, VTE (hazard ratio, 1.58; 95% CI, 1.23 to 2.02; p<0.001) was associated with poor overall survival.

CONCLUSIONS

Major vessel invasion is related to the occurrence of VTE in advanced CCA. The development of VTE significantly decreases the overall survival and is an important unfavorable prognostic factor for survival.

摘要

背景/目的:患有活动性癌症的患者常发生静脉血栓栓塞症(VTE)。然而,关于晚期胆管癌(CCA)患者的 VTE 数据很少。因此,我们研究了 VTE 在晚期 CCA 患者中的临床意义。

方法

我们在这项回顾性研究中分析了 2010 年至 2020 年间共 332 例不可切除的 CCA 患者的数据。我们研究了 VTE 的发生率和危险因素,以及其对晚期 CCA 患者生存的影响。

结果

在中位随访 11.6 个月期间,118 例患者(35.5%)发生了 VTE。VTE 的累积发生率在 3 个月时为 22.4%(95%置信区间 [CI],0.18 至 0.27),在 12 个月时为 32.8%(95% CI,0.27 至 0.38)。大血管侵犯是 VTE 的独立危险因素(风险比,2.88;95% CI,1.92 至 4.31;p<0.001)。在随访期间发生 VTE 的患者的总生存期短于未发生 VTE 的患者(11.50 个月比 15.83 个月,p=0.005)。在多变量分析中,VTE(风险比,1.58;95% CI,1.23 至 2.02;p<0.001)与总体生存不良相关。

结论

大血管侵犯与晚期 CCA 中 VTE 的发生有关。VTE 的发生显著降低了总生存期,是影响生存的重要不良预后因素。

相似文献

1
Clinical Significance of Venous Thromboembolism in Patients with Advanced Cholangiocarcinoma.晚期胆管癌患者静脉血栓栓塞的临床意义。
Gut Liver. 2024 Jan 15;18(1):165-173. doi: 10.5009/gnl220477. Epub 2023 Apr 3.
2
Venous thromboembolism in patients with cholangiocarcinoma: focus on risk factors and impact on survival.胆管癌患者的静脉血栓栓塞症:聚焦危险因素及其对生存的影响。
Eur J Gastroenterol Hepatol. 2012 Apr;24(4):444-9. doi: 10.1097/MEG.0b013e328350f93c.
3
Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes.新诊断胰腺癌患者静脉血栓栓塞症的发生率及其与结局相关的因素。
Gastroenterology. 2020 Apr;158(5):1346-1358.e4. doi: 10.1053/j.gastro.2019.12.009. Epub 2019 Dec 14.
4
Predictors for thromboembolism in patients with cholangiocarcinoma.预测胆管癌患者血栓栓塞的因素。
J Cancer Res Clin Oncol. 2022 Sep;148(9):2415-2426. doi: 10.1007/s00432-021-03794-1. Epub 2021 Sep 9.
5
Venous thromboembolism in patients undergoing distal cholangiocarcinoma surgery: Prevalence, risk factors, and outcomes.远端胆管癌手术患者的静脉血栓栓塞症:发生率、危险因素和结局。
Asian J Surg. 2023 Sep;46(9):3648-3655. doi: 10.1016/j.asjsur.2023.02.015. Epub 2023 Feb 14.
6
Venous Thromboembolism in Patients with Advanced Pancreatic Cancer Receiving Palliative Chemotherapy: Incidence and Effect on Prognosis.晚期胰腺癌接受姑息化疗患者的静脉血栓栓塞症:发生率及其对预后的影响。
Korean J Gastroenterol. 2023 Mar 25;81(3):109-120. doi: 10.4166/kjg.2022.137.
7
Venous Thromboembolism Is an Independent Predictor of Mortality Among Patients with Gastric Cancer.静脉血栓栓塞是胃癌患者死亡率的独立预测因素。
J Gastrointest Cancer. 2018 Dec;49(4):415-421. doi: 10.1007/s12029-017-9981-2.
8
Significance of venous thromboembolism in women with cervical cancer.静脉血栓栓塞在宫颈癌女性患者中的意义。
Gynecol Oncol. 2016 Sep;142(3):405-12. doi: 10.1016/j.ygyno.2016.06.012. Epub 2016 Jun 25.
9
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.欧洲胆管癌全景:ENSCCA 注册中心的诊断、预后和治疗见解。
J Hepatol. 2022 May;76(5):1109-1121. doi: 10.1016/j.jhep.2021.12.010. Epub 2022 Feb 12.
10
Venous thromboembolism in metastatic pancreatic cancer.转移性胰腺癌中的静脉血栓栓塞症。
Eur J Haematol. 2023 Jun;110(6):706-714. doi: 10.1111/ejh.13955. Epub 2023 Mar 30.

引用本文的文献

1
Venous thromboembolic complications in patients newly diagnosed with cholangiocarcinoma.新诊断胆管癌患者的静脉血栓栓塞并发症
J Thromb Thrombolysis. 2025 Apr;58(4):566-575. doi: 10.1007/s11239-025-03099-x. Epub 2025 Apr 11.
2
Machine learning-based prediction of pulmonary embolism to reduce unnecessary computed tomography scans in gastrointestinal cancer patients: a retrospective multicenter study.基于机器学习的肺栓塞预测模型以减少胃肠道癌症患者不必要的 CT 扫描:一项回顾性多中心研究。
Sci Rep. 2024 Oct 25;14(1):25359. doi: 10.1038/s41598-024-75977-y.
3
Interplay of Cardiometabolic Syndrome and Biliary Tract Cancer: A Comprehensive Analysis with Gender-Specific Insights.

本文引用的文献

1
Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis.吉西他滨、顺铂和 Nab-紫杉醇化疗方案治疗晚期胆道癌的真实世界结局:倾向评分匹配分析。
Gut Liver. 2022 Sep 15;16(5):798-805. doi: 10.5009/gnl210346. Epub 2022 Jan 7.
2
Genetic, Clinicopathological, and Radiological Features of Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation Pattern.具有胆管板畸形模式的肝内胆管细胞癌的遗传、临床病理和影像学特征。
Gut Liver. 2022 Jul 15;16(4):613-624. doi: 10.5009/gnl210174. Epub 2021 Nov 23.
3
Blocking VCAM-1 inhibits pancreatic tumour progression and cancer-associated thrombosis/thromboembolism.
心血管代谢综合征与胆道癌的相互作用:一项具有性别特异性见解的综合分析。
Cancers (Basel). 2024 Oct 9;16(19):3432. doi: 10.3390/cancers16193432.
阻断 VCAM-1 可抑制胰腺肿瘤进展和癌相关的血栓形成/血栓栓塞。
Gut. 2021 Sep;70(9):1713-1723. doi: 10.1136/gutjnl-2020-320608. Epub 2020 Oct 21.
4
Radiologic Evaluation and Structured Reporting Form for Extrahepatic Bile Duct Cancer: 2019 Consensus Recommendations from the Korean Society of Abdominal Radiology.肝外胆管癌的放射学评估和结构化报告表:韩国腹部放射学会 2019 年共识建议。
Korean J Radiol. 2021 Jan;22(1):41-62. doi: 10.3348/kjr.2019.0803. Epub 2020 Aug 28.
5
Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis.癌症相关血栓形成的治疗和预防临床实践指南。
Thromb Res. 2020 Jul;191 Suppl 1:S79-S84. doi: 10.1016/S0049-3848(20)30402-3.
6
Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes.新诊断胰腺癌患者静脉血栓栓塞症的发生率及其与结局相关的因素。
Gastroenterology. 2020 Apr;158(5):1346-1358.e4. doi: 10.1053/j.gastro.2019.12.009. Epub 2019 Dec 14.
7
Prediction of Portal Vein Thrombosis Following Hepatectomy for Perihilar Cholangiocarcinoma: Efficacy of Postoperative Portal Vein Diameter Ratio and Angle.肝门部胆管癌切除术后门静脉血栓形成的预测:术后门静脉直径比和角度的疗效。
Anticancer Res. 2019 Sep;39(9):5019-5026. doi: 10.21873/anticanres.13692.
8
Mechanism and management of cancer-associated thrombosis.癌症相关血栓形成的机制与管理
J Cardiol. 2018 Aug;72(2):89-93. doi: 10.1016/j.jjcc.2018.02.011. Epub 2018 Mar 24.
9
Prediction of thromboembolic complications after liver resection for cholangiocarcinoma: is there a place for thromboelastometry?胆管癌肝切除术后血栓栓塞并发症的预测:血栓弹力图有一席之地吗?
Blood Coagul Fibrinolysis. 2018 Jan;29(1):61-66. doi: 10.1097/MBC.0000000000000672.
10
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.胆管癌:ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2016 Sep;27(suppl 5):v28-v37. doi: 10.1093/annonc/mdw324.